Key facts
- Scala Biodesign’s last known valuation is $30.3M (Mar 2026).
- It has raised $21.6M; the latest was Early Stage VC ($16.0M) in Mar 2026.
- Notable investors include Innovation Authority, TLV Partners, Bullet Ventures, Deep Insight (Herzliya), Grove Ventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Scala Biodesign
- ·The full record, as it builds
Funding rounds
No funding rounds for Scala Biodesign are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Scala Biodesign
Provider of computational services intended to accelerate the development of proteins into commercial products. The company offers evolutionary analysis, atomistic protein design calculations, and artificial intelligence to design proteins with superior properties, enabling pharmaceutical, chemical, and sustainability industries to develop commercial products faster and more effectively.
- Sector
- Business Products and Services (B2B)
- HQ
- Tel Aviv, Israel
- Founded
- 2022
- Employees
- 28
- Website
- scala-bio.com/
- Ownership
- Privately Held (backing)
Scala Biodesign doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Scala Biodesign shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Scala Biodesign in its N-PORT filings yet. We sweep new filings monthly.